Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lcr35 for Prevention of Bacterial Vaginosis Recurrence
NCT01160796Phase 3Completed
- Sponsor
- Laboratoires Lyocentre
- Start
- Jun 2010
- Primary completion
- May 2011
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bacterial vaginosis (BV) comparing Lcr35 with Placebo (2 arms). Primary endpoint: Mean time before the onset of first clinical recurrence confirmed by laboratory tests at 4 months. Started Jun 2010; status: completed.
02
Drugs
lactobacillus rhamnosus Lcr35
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on NCT01160796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01160796.